Back to top
more

MEI Pharma (MEIP)

(Delayed Data from NSDQ)

$3.06 USD

3.06
17,147

0.00 (0.00%)

Updated May 3, 2024 04:00 PM ET

After-Market: $3.07 +0.01 (0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD

by Zacks Equity Research

The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickle cell disease. Shares rise.

AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.

Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse

by Zacks Equity Research

The FDA accepts Catalyst's (CPRX) sNDA to increase the indicated maximum daily dosage of Firdapse 10 mg from 80mg to 100mg for treating Lambert-Eaton myasthenic syndrome. The decision is due on Jun 4, 2024.

All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy

by Zacks Equity Research

MEI Pharma, Inc. (MEIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Procaps Group, S.A. (PROC) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Procaps Group, S.A. (PROC) delivered earnings and revenue surprises of 350% and 2.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Q4 Earnings Miss Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of -10% and 1.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharma (INFI) Stock Up on Advancing Cancer Study

by Zacks Equity Research

Infinity Pharma (INFI) provides insights on the phase II MARIO-8 study design. The study will evaluate eganelisib for squamous cell cancer of the head and neck.

MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 10.77% and 501.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -58.82% and 4.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -153.85% and 12.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of 11.11% and 24.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CV Sciences, Inc. (CVSI) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 50% and 6.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of -5.77% and 66.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Impel Pharmaceuticals Inc. (IMPL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -8.33% and 9.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -8.70% and 27.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -164.71% and 96.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Q1 Earnings Miss Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of -13.51% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug

by Zacks Equity Research

Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Will MEI Pharma, Inc. (MEIP) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About MEI Pharma (MEIP) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to MEI Pharma (MEIP) stock based on the movements in the options market lately.

MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0.00% and 34.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?